Turbidimetric inhibition immunoassay (TINIA) for the in vitro determination of hemoglobin A1c in whole blood or hemolysate
Diabetes mellitus, ranking 9th in the top ten global cuases of deaths, has become a worldwide health topic.1 In 2019, more than one in 10 adults is living with diabetes (537 million) with approximately 45% of adults having undiagnosed diabetes.2
HbA1c, which reflects the average glucose level in the last 8-12 weeks, is one of the most widely used test in diabetes management. Current ADA guidelines recommend the HbA1c tests for use in diagnosing type 2 diabetes and prediabetes.3 Therefore, it is critical for the lab to use a standardized assay with good quality to support the right clinical decision.
On cobas® series platforms, the Tina-quant® HbA1c assay empowers the laboratory to reduce TAT, optimize operational cost with various solutions, and build confidence on the results for clinical decisions.
The Tina-quant® HbA1c assay aims to meet all of your needs in HbA1c measurement for routine diabetes management. Each and every time!